Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
Completed · Phase 2 · Has a placebo group
Conditions studied: Amyotrophic Lateral Sclerosis
In brief
This study evaluates the effect of retigabine (600 mg/day, 900 mg/day, or placebo) on motor neuron activity in people with Amyotrophic Lateral Sclerosis (ALS). The total study duration is approximately 14 weeks. ALS subjects will take study drug for approximately 10 weeks.
Key facts
- Study ID
- NCT02450552
- Run by
- Brian Wainger
- People needed
- 65
- Starts
- 2015-06-01
- Expected to finish
- 2018-02-01
- Last updated by the study team
- 2019-08-28
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.
Where it is running
- Barrow Neuological Institute — Phoenix, Arizona, United States
- Cedars-Sinai — Los Angeles, California, United States
- UC Irvine Medical Center — Orange, California, United States
- Mayo Clinic in Florida — Jacksonville, Florida, United States
- Augusta University (Georgia Regents Medical Center) — Augusta, Georgia, United States
- Johns Hopkins Hospital — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Hospital for Special Surgery — New York, New York, United States
- Duke University Hospital — Durham, North Carolina, United States
- Penn State College of Medicine Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.